GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has entered into a warrant inducement agreement with an existing institutional investor. The agreement facilitates the immediate exercise of existing warrants to purchase up to 5,697,628 shares of common stock at an exercise price of $0.64 per share, yielding gross cash proceeds of approximately $3,646,482 before deducting financial advisor fees and other transaction expenses.
In consideration for the immediate exercise of the existing warrants, the investor will receive new unregistered warrants to purchase up to 11,395,256 shares of common stock (the "New Warrants"). The New Warrants will have an exercise price of $0.64, become exercisable on the date shareholder approval is obtained for the issuance of shares underlying the New Warrants, and expire five years following that approval date. The transaction is expected to close on or about August 27, 2026, subject to customary closing conditions.
The company intends to use the net proceeds from the offering for working capital and other general corporate purposes. This strategic move provides GeoVax with additional financial flexibility as it advances its pipeline, including its lead program GEO-MVA, a modified vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, which is planned to enter a pivotal Phase 3 clinical trial in the second half of 2026. The company is also developing Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, which has completed a Phase 1/2 trial in head and neck cancer.
The private placement of the New Warrants and underlying shares will be made in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. As such, the securities may not be offered or sold in the United States absent registration or an applicable exemption.
This financing underscores GeoVax's commitment to advancing its clinical programs and addressing critical global needs in infectious disease and oncology. The company's focus on biodefense preparedness and expanding orthopoxvirus vaccine supply aligns with its strategic priorities. With this capital infusion, GeoVax is better positioned to execute its development plans and pursue strategic partnerships.
The warrant inducement transaction is a common financing mechanism for clinical-stage biotech companies, providing immediate capital while offering investors additional upside potential through the issuance of new warrants. This approach allows GeoVax to secure funding without immediate dilution beyond the existing warrants' exercise, as the new warrants are exercisable only after shareholder approval.
As GeoVax progresses toward key clinical milestones, including the pivotal Phase 3 trial for GEO-MVA, the additional working capital will support operational needs and general corporate purposes. The company's ability to secure this financing reflects investor confidence in its pipeline and strategic direction.
